Cardiovascular outcomes, heart failure, cardio-renal protection, hypertension, and lipid-lowering trials in diabetes and endocrinology.
An RCT finds intraoperative dexmedetomidine reduces glucose variability, insulin requirements, and CRP in diabetic off-pump CABG patients, though endpoints are surrogate. PICO summary and commentary.
A prespecified BRIGHT-4 subgroup analysis finds bivalirudin reduces death or major bleeding versus heparin in lower-BMI STEMI patients but not higher-BMI, with a significant interaction. PICO summary and commentary.
A four-arm RCT finds exercise plus broccoli sprouts improves apolipoproteins in men with type 2 diabetes, but the benefit is mainly exercise-driven. PICO summary and commentary.
A small RCT finds a 12-week hybrid Tai Chi cardiac rehab programme reduces perceived stress and oxidised LDL more than conventional exercise in chronic coronary syndrome. PICO summary and commentary.
A lipidomics analysis from the randomised EmDia trial finds empagliflozin remodels plasma lipids in type 2 diabetes, raising beneficial LPCs but also harmful ceramides. PICO summary and commentary.
An OPTION post-hoc analysis finds indobufen-based antiplatelet therapy after stenting performs consistently regardless of diabetes status, with a similar bleeding advantage. PICO summary and commentary.
A prespecified SUMMIT analysis finds tirzepatide reduces heart-failure events in obese HFpEF regardless of diabetes status, despite less weight loss with diabetes. PICO summary and commentary.
The 4-year DAPAHEART follow-up finds dapagliflozin raises coronary flow reserve by 34% and reduces epicardial fat, apparently independent of weight loss. PICO summary and commentary.
Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.
© 2024-2026 Hormone Insight. All rights reserved.
